I wa doing continued DD on this company when I came across some information that seems another company is working on the same thing as CNDO. It is called Asphelia Pharmaceuticals and their whipworm trial med is called ASP1002? Has anyone heard of them and is this company a possible competitor of CNDO?I
I also listened to the latest investor forum on April 9th. Understood the reason for choosing Pig whipworms, T. Suis, and the advantages it has over some other parasites, but does anyone else see a possible problem for CNDO if another biopharm can compete by using some other pathogen or parasites? I understand that the mechanism of action of using parasites to treat auto-immune disease is still not well understood and research is ongoing (ie research agreement with Freie Universität Berlin). I see this as a positive but also see this as a door open for other parasites to treat autoimmune diseases. One example I found was an Argentina study on MS using, schistosoma mansoni. Thanks for any feedback!
You're wrong. In the very first page fo CNDO called "History" website it is said and I quote "In January 2011, Coronado ACQUIRED the assets of Asphelia Pharmaceuticals, Inc. relating to TSO (Trichuris suis ova or CNDO-201), a novel immunotherapy being developed for the treatment of Crohn’s disease, ulcerative colitis, multiple sclerosis and several other autoimmune disorders. These assets INCLUDE exclusive rights to TSO in North America, South America and Japan under a sublicense agreement with OvaMed GmbH (OvaMed). In March 2012, Coronado entered into a Collaboration Agreement with OvaMed and Dr. Falk Pharma GmbH, OvaMed's sublicensee in Europe for gastroenterology indications, for the development of TSO for Crohn's disease."
Also just Google "Coronado Biosciences (CNDO) Buys TSO Manufacturing Rights From Ovamed." and you will learn the following : "As part of the transaction, Coronado entered into a lease agreement to establish a manufacturing facility in Woburn, Massachusetts to produce TSO (Trichuris suis ova or CNDO-201), which is a biologic for the treatment of autoimmune diseases such as Crohn's disease, ulcerative colitis and multiple sclerosis.
Coronado entered into amendments to its existing license and supply agreements with Ovamed expanding Coronado's exclusive license to include TSO manufacturing rights in Coronado's territory and terminating Ovamed's exclusive supply rights once Coronado's planned manufacturing facility is operational."
A DD is a DD ! Many people don't do their homework correctly and let believe at others some nonsense.